Western Acquisition Ventures Corp. Shares Resume Trading
Save time and jump to the most important pieces.
SC 13G/A - Western Acquisition Ventures Corp. (0001868419) (Subject)
SC 13G/A - Western Acquisition Ventures Corp. (0001868419) (Subject)
SC 13G - Western Acquisition Ventures Corp. (0001868419) (Subject)
Emmit McHenry, founder and acclaimed technology innovator, to continue serving as Chairman of the BoardMCLEAN, VA / ACCESSWIRE / February 14, 2023 / Cycurion, Inc. (the "Company" or "Cycurion"), a leading provider of tech-enabled cybersecurity solutions, today announced that L. Kevin Kelly will succeed Emmit McHenry as Chief Executive Officer effective February 14, 2023. Mr. McHenry will continue to serve as Chairman of the Board, focusing his expertise and deep industry knowledge on Cycurion's strategic growth plan. The leadership transition further strengthens Cycurion's senior team as it prepares to become a public company via merger with Western Acquisition Ventures Corp."I am honored to
NEW YORK, NY / ACCESSWIRE / January 9, 2023 / Western Acquisition Ventures Corp. (NASDAQ:WAVS) ("Western," "the Company"), a special purpose acquisition company, today announced that at a special meeting of its stockholders held January 6th, stockholders approved an extension to the time period that the Company has to consummate its business combination. The extension was approved for a one-month period up to six times, and the Company now has until July 11, 2023, to complete the transaction.In connection with the extension, Western amended the Company's charter and is now expected to deposit into the Trust Account of the Company $10,000 for each one-month extension up to an aggregate $60,00
Cycurion serves a massive market for cybersecurity solutions estimated at $174 billion with significant secular tailwinds for growth given the rapid proliferation and severity of cyber threats;Cycurion provides Managed Security, Managed IT and Consulting/Advisory services and solutions. In addition, Cycurion offers the Cycurion ARx Security platform which is a multilayer software platform that consists of a Web Application Firewall, Bot Mitigation and Geo Gating;Cycurion's platform is built on a set of proprietary algorithms that provide multiple layers of protection from attacks that provides the C-Suite with real-time information on the organization's cyber posture;Established base of blue
NT 10-Q - Western Acquisition Ventures Corp. (0001868419) (Filer)
S-4/A - Western Acquisition Ventures Corp. (0001868419) (Filer)
8-K - Western Acquisition Ventures Corp. (0001868419) (Filer)
Emmit McHenry, founder and acclaimed technology innovator, to continue serving as Chairman of the BoardMCLEAN, VA / ACCESSWIRE / February 14, 2023 / Cycurion, Inc. (the "Company" or "Cycurion"), a leading provider of tech-enabled cybersecurity solutions, today announced that L. Kevin Kelly will succeed Emmit McHenry as Chief Executive Officer effective February 14, 2023. Mr. McHenry will continue to serve as Chairman of the Board, focusing his expertise and deep industry knowledge on Cycurion's strategic growth plan. The leadership transition further strengthens Cycurion's senior team as it prepares to become a public company via merger with Western Acquisition Ventures Corp."I am honored to
Western Acquisition Ventures Corp. (NASDAQ:WAVS) ("Western"), a special purpose acquisition company, today announced that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on June 5, 2024 (the "Notice"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the "Form 10-Q"), as described more fully in the Company's Form 12b-25 Notification of Late Filing (the "Form 12b-25") filed with the Securities and Exchange Commission (the "SEC")
- SEC Filing
Gainers ProMIS Neurosciences, Inc. (NASDAQ:PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived antibody and vaccine from Alzheimer's pipeline. Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) shares climbed 61.5% to $10.14 after the company presented topline results from Phase 1 study of ACU193 for early Alzheimer's disease at the Alzheimer's Association International Conference 2023. BridgeBio Pharma, Inc. (NASDAQ:BBIO) gained 60.8% to $29.30 after the company's Phase 3 ATTRibute-CM study of acoramidis for transthyretin amyloid cardiomyopathy met its primary endpoint. Lixte Biotechnol